Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30910863 | 0.99 | SIGMAR1 (0.44) | SIGMAR1HRH3DPP8XIAP | |
| SCHEMBL21910362 | 0.88 | SIGMAR1 (0.46) | SIGMAR1HRH3XIAP | |
| SCHEMBL26945839 | 0.88 | SIGMAR1 (0.46) | SIGMAR1HRH3XIAP | |
| Hydrochloric Acid SCHEMBL25329238 | 0.86 | SIGMAR1 (0.46) | SIGMAR1HRH3XIAP | |
| Hydrochloric Acid SCHEMBL21831296 | 0.86 | SIGMAR1 (0.46) | SIGMAR1HRH3XIAP | |
| Hydrochloric Acid SCHEMBL26925778 | 0.86 | SIGMAR1 (0.46) | SIGMAR1HRH3XIAP | |
| SCHEMBL26925439 | 0.86 | SIGMAR1 (0.46) | SIGMAR1HRH3DPP8 | |
| Hydrochloric Acid SCHEMBL26925963 | 0.85 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8 | |
| SCHEMBL21910774 | 0.82 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8XIAP | |
| SCHEMBL21910443 | 0.82 | SIGMAR1 (0.45) | SIGMAR1HRH3DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885HRH3 741/4885DPP8 3019/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885HRH3 741/4885DPP8 3019/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885HRH3 741/4885DPP8 3019/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885HRH3 741/4885DPP8 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.